Seize the Day! Lately that’s been my morning mental mantra. I visualize it as a chant and it’s the secret weapon I use every December to help me adjust to the onset of winter and face the end of the year. Even though I’m lucky to live…
Seize the Day and Chase Winter Doldrums Away
BrainStorm Cell Therapeutics released new data on potential biomarkers from its Phase 2 trial investigating NurOwn, the company’s cell therapy for amyotrophic lateral sclerosis (ALS), at the International Symposium on ALS/MND meeting held in Boston last week. Both these findings and an ongoing Phase 3 trial, now recruiting patients in…
Pivotal Phase 3 clinical trial results presented at this year’s 28th International Symposium on ALS/MND reveal that Cytokinetics‘ investigational therapy tirasemtiv failed to provide a positive therapeutic impact on both muscle strength and slow vital capacity (SVC) in ALS patients. The results, which were presented by Jeremy Shefner, MD,…
The rate of ALS patients’ lung-function decline can predict their risk of breathing failure, their need for assisted ventilation, and their risk of death, according to Cytokinetics, a company that develops muscle-disease therapies. “These results suggest that respiratory function is an important prognostic indicator of clinical progression in people with…
Additional data on Radicava (edaravone) and the clinical trial that led to its approval to treat amyotrophic lateral sclerosis (ALS) will be presented in oral and poster presentations at the 28th International Symposium on ALS/MND that opens in Boston on Friday. Mitsubishi Tanabe Pharma America announced that its one oral…
Understanding Molecular Changes in ALS
In this TEDx Talks video, Steven Boeynaems explains that although we have known about amyotrophic lateral sclerosis (ALS) for 140 years, scientists still know very little about the condition that affects around 200,000 people worldwide. MORE: Seven interesting facts about ALS Boeynaems talks about the role of TDP-43 proteins and…
Using stem cell treatments to protect motor neurons is not enough to prevent the loss of nerve-muscle connections and disease progression in a mouse model of amyotrophic lateral sclerosis (ALS), researchers from Italy found. The study, published in the journal Stem Cell Research, had exposed mice to repeated brain…
Takeda Canada and the Montreal Neurological Institute (MNI) are teaming up to conduct joint research aimed at developing new therapies for amyotrophic lateral sclerosis (ALS). The collaborative effort includes developing and examining multiple cell assays from ALS patients over the next three years, from 2017 to 2020,…
Join the ALS Boogie Board Club
OK, so now I’m an official member of the ALS Boogie Board Club! No, it’s not a club for surfer-dudes with ALS. I’m using a Boogie Board Jot 8.5 eWriter, a unique gadget that replaces writing with pen and paper. I received it during my recent visit to the…
The U.S. Department of Veterans Affairs (VA) has added Radicava (edaravone) to its national formulary (VANF), making it possible for veterans with amyotrophic lateral sclerosis (ALS) to access treatment within the VA’s healthcare system, according to Mitsubishi Tanabe Pharma America (MTPA). The VANF is a list of drugs and…
Recent Posts
- Blood NfL levels linked to higher ALS risk years before onset
- After promising early results, ALS drug moves toward new, larger trial
- MDA Engage: California event highlights community connection
- Partnership to boost communication support for people with ALS
- ‘Nobody knows how to say goodbye’ in life with ALS